Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and ...
Esperion (ESPR) has filed New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications ...
Esperion shares were up 13% to $3.16 after the company said it has filed New Drug Submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein ...
If you have high cholesterol, your doctor may prescribe you with a type of statin. Here’s what you need to know. Statins are a group of medications used to treat high cholesterol. They work by ...
A UCLA study has outlined a new framework that researchers say would improve the predictive power of genetics to determine ...
a class of drug that effectively reduces cholesterol. Guidelines for doctors do not recommend prescribing statins to diabetic patients unless they have high cholesterol levels. But the new ...
Overall, a 20% decrease in LDL cholesterol was seen. Participants reported that they would have found more information on drug interactions ... make statins unavailable to non-insured or indigent ...
has submitted New Drug Submissions to Health Canada for two cholesterol-lowering medications, NEXLETOL and NEXLIZET, the company announced today. These oral, non-statin drugs are designed to ...
The patient asked: "I have high cholesterol, but when I tried statins, I didn't like the side effects. What are non-pharmaceutical ways ... to the impact of older statin drugs from the '90s.
ANN ARBOR, Mich. - Esperion (NASDAQ: NASDAQ:ESPR), which has seen remarkable revenue growth of 187% over the last twelve months, has submitted New Drug Submissions to Health Canada for two cholesterol ...
A new study has outlined a new framework that researchers say would improve predictive power of genetics to determine how well a patient would respond to commonly prescribed medications as well as the ...
Published in the journal Cell Genomics, the study found that data from large libraries of sequenced human genomes and other ...